FRAMINGHAM, Mass.–KalVista Pharmaceuticals, now part of the Chiesi Group, is presenting new clinical and real-world research on sebetralstat, a treatment for hereditary angioedema (HAE), at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona, November 12-16.
The research includes five scientific presentations examining patient satisfaction, treatment preferences, long-term quality of life, healthcare utilization among adolescents and the burden experienced by caregivers of people living with HAE.
The presentations are intended to provide additional insight into how patients experience treatment and manage the disease in everyday settings, extending beyond traditional measures of clinical effectiveness.
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling that can affect the skin, gastrointestinal tract and airways. Attacks can be unpredictable and, when they involve the throat, potentially life-threatening.
“With our acquisition of KalVista Pharmaceuticals, the addition of sebetralstat to our rare immunology portfolio marks a major milestone in Chiesi’s longstanding commitment to rare disease communities,” said Giacomo Chiesi, Executive Vice President of Chiesi Global Rare Diseases. “As we build on KalVista’s deep expertise in HAE, close collaboration with the scientific and patient communities will remain essential to deepening our understanding of lived experiences and advancing care for people living with rare diseases today and for generations to come.”
The five presentations examine several aspects of HAE treatment, including why patients switch therapies and how treatment satisfaction can influence disease management.
Other research focuses on long-term health-related quality-of-life outcomes, healthcare resource utilization among adolescent patients and the effects of the disease on caregivers.
According to KalVista, the findings contribute to a growing body of clinical and real-world evidence evaluating sebetralstat, including research presented earlier this year at the 2026 HAEi Regional Conference Americas and Bradykinin Symposium 2026.
The company said the additional research is intended to help clinicians better understand treatment experiences across different patient populations, including children and adolescents.
“Real-world evidence and patient-reported outcomes provide important insights into clinical practice and the everyday realities of managing HAE,” said William R. Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and Medical Director of AARA Research Center in Dallas. “Understanding patient satisfaction, treatment preferences and quality-of-life factors helps us better evaluate the full impact of disease management. As clinicians, we are encouraged by the ongoing research that expands our understanding of HAE across both adult and pediatric populations as it can help inform care and potentially expand treatment options.”
The research also examines the emotional and practical challenges associated with managing HAE, including decisions about when to administer treatment and how patients respond to unpredictable attacks.
Rachele Berria, M.D., Ph.D., Senior Vice President of Medical Affairs at Chiesi Group, said evaluating the broader patient experience is an important component of developing treatment strategies.
“The presentations at ACAAI reflect a research approach that looks beyond efficacy to the full treatment experience, including the emotional and practical factors that influence when and how people manage their attacks,” Berria said. “The real-world evidence and quality-of-life data offer valuable perspective on the lived experiences of people with HAE and the considerations healthcare professionals need to take into account when making treatment decisions. These insights are increasingly important as we work to align treatment strategies with patient preferences and advance our clinical research across age groups.”
KalVista’s integration into Chiesi Global Rare Diseases expands the group’s rare immunology portfolio and provides additional resources for ongoing HAE research and development.
The companies plan to continue working with researchers, healthcare professionals and patient organizations to investigate treatment experiences and improve understanding of HAE across different age groups.
The research presented at ACAAI is part of those efforts, with an emphasis on incorporating patient-reported outcomes and real-world evidence into clinical decision-making and future research.
